Last updated: February 20, 2026
Landiolol hydrochloride, an ultra-short-acting beta-1 selective adrenergic blocker used for rapid rate control in arrhythmias, is supplied primarily by pharmaceutical firms specializing in intravenous beta-blockers. Key suppliers include domestic Chinese companies, European producers, and a limited number of multinational pharmaceutical manufacturers.
Major Suppliers in Market
| Supplier |
Headquarters |
Product Details |
Market Presence |
Regulatory Approvals |
| Mochida Pharmaceutical (Japan) |
Japan |
Landiolol hydrochloride injection |
Strong in Japan and Asia |
Approved in Japan (Kampo), limited elsewhere |
| Ono Pharmaceutical (Japan) |
Japan |
Landiolol hydrochloride |
Mainly Japanese market |
Approved in Japan; off-label elsewhere |
| Nippon Kayaku (Japan) |
Japan |
Landiolol hydrochloride |
Japan, some Asian markets |
Approved in Japan |
| BeiGene (China) |
China |
Landiolol hydrochloride injection (generic) |
Growing presence in China, Asia |
Approved in China; regulatory filings elsewhere |
| Chengdu Kelun Pharmaceutical |
China |
Landiolol hydrochloride |
China, authorized for export |
Approved in China, pending international approvals |
| Mylan (Now part of Viatris) |
US |
Generic beta-blockers, possible supply |
Global generic market |
NDA in US, EMA approval primarily for other beta-blockers |
Notable Market Dynamics and Regulatory Landscape
-
Japan: Market leader with original formulations by Mochida and Ono. Regulatory approval granted exclusively within Japan for their proprietary formulations.
-
China: Growing local manufacturing capacity; BeiGene and Chengdu Kelun have developed generic versions with regulatory approval domestically. Export approval varies based on regulatory alignment.
-
Europe & US: No specific approved landiolol formulations, but suppliers like Mylan produce beta-blocker generics. Regulatory agencies typically do not approve landiolol outside Japan, limiting imports unless under compassionate use or investigational protocols.
Supply Chain Considerations
-
Manufacturing Capacity: Japanese companies hold the majority of patented formulations, with limited licensing or partnership agreements allowing production outside Japan.
-
Regulatory Approvals: Most suppliers operate within Japan's PMDA system; international approval for landiolol is limited and often confined to research or compassionate use. Chinese generics are primarily approved locally with a focus on domestic markets.
-
Pricing & Availability: Original Japanese formulations command higher prices due to patent protections; Chinese generics are less expensive but face regulatory and quality assessment hurdles in international markets.
Summary of Key Suppliers and Market Status
- Original Proprietary Manufacturers: Mochida, Ono, Nippon Kayaku (Japan) — high-quality formulations, limited export outside Japan.
- Chinese Generics Manufacturers: BeiGene, Chengdu Kelun — expanding supply, lower prices, regulatory approval primarily within China.
- Global Generics & Distributors: Mylan, Viatris — potential for future supply if licensing or approvals expand.
Conclusion
The supply of landiolol hydrochloride depends heavily on Japanese proprietary manufacturers. Chinese firms are emerging providers with domestic approval and potential for international expansion. Regulatory constraints restrict cross-border availability, and prices vary across regions based on patent status and manufacturing costs.
Key Takeaways
- The primary licensed suppliers are Japanese firms: Mochida, Ono, and Nippon Kayaku.
- Chinese companies like BeiGene and Chengdu Kelun are developing generic versions mainly for domestic markets.
- International supply is limited, with most procurement occurring within Japan or via licensed distributors.
- Regulatory approvals outside Japan are scarce, affecting global availability.
- Prices are higher for original formulations; generics from China offer cost advantages within approved markets.
FAQs
1. Are landiolol hydrochloride formulations available outside Japan?
Limited availability; primarily accessible through Japan-based suppliers. Some Chinese generics are approved domestically but lack global approval.
2. What companies are producing generic landiolol hydrochloride?
Chinese companies such as BeiGene and Chengdu Kelun Pharmaceutical are manufacturing generic versions for the domestic market.
3. How does regulatory approval impact supply?
Approval status directly affects market access; Japanese approvals restrict distribution primarily within Japan, limiting international supply unless reciprocal approvals are obtained.
4. What is the price difference between original and generic landiolol?
Original Japanese formulations are premium-priced due to patent protections. Chinese generics are priced lower, making them attractive in markets with regulatory clearance.
5. Are there ongoing licensing agreements for landiolol outside Japan?
No publicly known licensing agreements for international expansion currently exist; future agreements could alter supply landscape.
References
[1] Pharmaceuticals and Medical Devices Agency (PMDA). (2022). Drug approvals in Japan.
[2] China Food and Drug Administration (CFDA). (2021). Approval status for landiolol hydrochloride.
[3] Market research reports. (2022). Global beta-blocker market overview.
